Quillichew ER vs. Adzenys ER

• Are Quillichew ER and Adzenys ER the Same Thing?
• What Are Possible Side Effects of Quillichew ER?
• What Are Possible Side Effects of Adzenys ER?
• What Is Quillichew ER?
• What Is Adzenys ER?
• What Drugs Interact with Quillichew ER?
• What Drugs Interact with Adzenys ER?
• How Should Quillichew ER Be Taken?
• How Should Adzenys ER Be Taken?

QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets and Adzenys ER (amphetamine) extended-release oral suspension are central nervous system (CNS) stimulants used to treat attention deficit hyperactivity disorder (ADHD).

Side effects of QuilliChew ER and Adzenys ER that are similar include weight loss, dizziness, mood swings, rapid heart rate, decreased appetite, headache, nausea, vomiting, abdominal pain, dry mouth, sleep problems (insomnia), nervousness, agitation, or fever.

Side effects of QuilliChew ER that are different from Adzenys ER include anxiety, irritability, aggression, indigestion, restlessness, spinning sensation (vertigo), tremor, blurred vision, palpitations, increased sweating, fever, and increased blood pressure.

Side effects of Adzenys ER that are different from QuilliChew ER include diarrhea, weakness or lack of energy, or urinary tract infections (UTIs).

Both QuilliChew ER and may interact with monoamine oxidase inhibitors (MAOIs).

Adzenys ER may also interact with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort, sodium bicarbonate, acetazolamide, some thiazides, quinidine, ritonavir, omeprazole, esomeprazole, pantoprazole, and cimetidine.

Withdrawal symptoms may occur if you suddenly stop taking QuilliChew ER or Adzenys ER.

Common side effects of Quillichew ER include:

• weight loss,
• anxiety,
• dizziness,
• irritability,
• mood swings,
• rapid heart rate,
• decreased appetite,
• aggression,
• headache,
• nausea,
• abdominal pain,
• indigestion,
• dry mouth,
• vomiting,
• insomnia,
• nervousness,
• restlessness,
• agitation,
• spinning sensation (vertigo),
• tremor,
• blurred vision,
• palpitations,
• increased sweating,
• fever, and
• increased blood pressure.

Common side effects of Adzenys ER include:

• loss of appetite,
• insomnia,
• abdominal pain,
• mood changes,
• vomiting,
• nervousness,
• nausea,
• fever,
• weight loss,
• and nervousness.

Common side effects of Adzenys ER for adult patients also include:

• dry mouth,
• headache,
• agitation,
• dizziness,
• fast heart rate,
• diarrhea,
• weakness or lack of energy,
• and urinary tract infections (UTIs).

QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Adzenys ER (amphetamine) extended-release oral suspension is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

QuilliChew ER may interact with monoamine oxidase inhibitors (MAOIs). Tell your doctor all medications and supplements you or your child uses. During pregnancy, QuilliChew ER should be used only if prescribed. It is unknown if it would affect a fetus. QuilliChew ER passes into breast milk. It is unknown if it would affect a nursing infant. Consult your doctor before breastfeeding. Withdrawal symptoms may occur if you suddenly stop taking QuilliChew ER.

Adzenys ER may interact with monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort, sodium bicarbonate, acetazolamide, some thiazides, quinidine, ritonavir, omeprazole, esomeprazole, pantoprazole, and cimetidine. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Adzenys ER; it may harm a fetus. Adzenys ER passes into breast milk. Large dosages of amphetamines such as Adzenys ER might interfere with milk production. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment with Adzenys ER. Withdrawal symptoms may occur if you suddenly stop taking Adzenys ER.

For patients 6 years and above, the recommended starting dose of QuilliChew ER is 20 mg given orally once daily in the morning.

The starting dose of Adzenys ER for pediatric patients (ages 6 to 17 years) is 6.3 mg (5 mL) once daily in the morning. Maximum dose is 18.8 mg (15 mL) for patients 6 to 12 years, and 12.5 mg (10 mL) once daily for patients 13 to 17 years. The dose of Adzenys ER for adults is 12.5 mg (10 mL) once daily in the morning.